Literature DB >> 26744963

Severe asthma gets first biologic in decades.

Anna Azvolinsky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26744963     DOI: 10.1038/nbt0116-10

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

Authors:  Ruth H Green; Christopher E Brightling; Susan McKenna; Beverley Hargadon; Debbie Parker; Peter Bradding; Andrew J Wardlaw; Ian D Pavord
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

2.  Anti-IL-5 biologics carve out severe-asthma niche.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2014-11       Impact factor: 54.908

3.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations.

Authors:  L Jayaram; M M Pizzichini; R J Cook; L-P Boulet; C Lemière; E Pizzichini; A Cartier; P Hussack; C H Goldsmith; M Laviolette; K Parameswaran; F E Hargreave
Journal:  Eur Respir J       Date:  2006-03       Impact factor: 16.671

4.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.

Authors:  Michel Laviolette; David L Gossage; Gail Gauvreau; Richard Leigh; Ron Olivenstein; Rohit Katial; William W Busse; Sally Wenzel; Yanping Wu; Vivekananda Datta; Roland Kolbeck; Nestor A Molfino
Journal:  J Allergy Clin Immunol       Date:  2013-07-16       Impact factor: 10.793

5.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

Authors:  Elisabeth H Bel; Sally E Wenzel; Philip J Thompson; Charlene M Prazma; Oliver N Keene; Steven W Yancey; Hector G Ortega; Ian D Pavord
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

6.  Mepolizumab treatment in patients with severe eosinophilic asthma.

Authors:  Hector G Ortega; Mark C Liu; Ian D Pavord; Guy G Brusselle; J Mark FitzGerald; Alfredo Chetta; Marc Humbert; Lynn E Katz; Oliver N Keene; Steven W Yancey; Pascal Chanez
Journal:  N Engl J Med       Date:  2014-09-08       Impact factor: 91.245

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.